Chikungunya Fever - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 101 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chikungunya Fever - Pipeline Review, H2 2016, provides an overview of the Chikungunya Fever (Infectious Disease) pipeline landscape.

Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family Togaviridae. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting and rash and fever. Treatment includes use of NSAIDs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chikungunya Fever - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chikungunya Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chikungunya Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 19 and 3 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 6 molecules, respectively for Chikungunya Fever.

Chikungunya Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chikungunya Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Chikungunya Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chikungunya Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chikungunya Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chikungunya Fever (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chikungunya Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chikungunya Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chikungunya Fever Overview 10
Therapeutics Development 11
Pipeline Products for Chikungunya Fever - Overview 11
Pipeline Products for Chikungunya Fever - Comparative Analysis 12
Chikungunya Fever - Therapeutics under Development by Companies 13
Chikungunya Fever - Therapeutics under Investigation by Universities/Institutes 15
Chikungunya Fever - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Chikungunya Fever - Products under Development by Companies 18
Chikungunya Fever - Products under Investigation by Universities/Institutes 19
Chikungunya Fever - Companies Involved in Therapeutics Development 20
Abivax S.A. 20
Arbovax, Inc. 21
Arno Therapeutics, Inc. 22
Bharat Biotech International Limited 23
Ennaid Therapeutics, LLC 24
Etubics Corporation 25
Hawaii Biotech, Inc. 26
HSRx Group 27
Indian Immunologicals Limited 28
Inovio Pharmaceuticals, Inc. 29
Integral Molecular, Inc. 30
Integrated BioTherapeutics, Inc. 31
Merck & Co., Inc. 32
Nanotherapeutics, Inc. 33
Profectus BioSciences, Inc. 34
Takeda Pharmaceutical Company Limited 35
Themis Bioscience GmbH 36
Valneva SE 37
Vaxart, Inc. 38
Chikungunya Fever - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
ABX-1089 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
ABX-1091 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
ABX-311 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Antibody for Chikungunya - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
AR-12 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
chikungunya (viral like particles) vaccine - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
chikungunya vaccine - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
chikungunya vaccine - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
chikungunya vaccine - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
chikungunya vaccine - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
chikungunya vaccine - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
chikungunya vaccine - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
chikungunya vaccine - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
chikungunya vaccine - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
chikungunya vaccine - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
chikungunya vaccine - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
chikungunya vaccine - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
chikungunya vaccine - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
chikungunya vaccine - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
chikungunya vaccine - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
chikungunya vaccine - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
chikungunya vaccine - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
DEF-201 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
HSRx-431 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
IMCKV-063 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Monoclonal Antibodies for Chikungunya - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Chikungunya and Ross River Virus Fever - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Monoclonal Antibody for Chikungunya - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
MV-CHIK - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Peptides for Infectious Diseases - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Small Molecule to Inhibit NS2 and NS3 for Chikungunya - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Small Molecules for Chikungunya - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Synthetic Peptides for Chikungunya - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Tatbeclin-1 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Chikungunya Fever - Dormant Projects 89
Chikungunya Fever - Product Development Milestones 90
Featured News & Press Releases 90
Aug 30, 2016: Hawaii Biotech Awarded Grant To Develop Chikungunya Virus Vaccine 90
Aug 25, 2016: Leading Chikungunya Vaccine in Clinical Trial Phase 2 91
Mar 22, 2016: Inovio's DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study 91
Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs 93
Mar 02, 2015: Themis Bioscience's Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases 94
Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus 95
Nov 20, 2014: Themis Bioscience's Vaccine Against Chikunguya Successful In Phase 1 96
Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful 97
Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate 97
Aug 15, 2011: Inviragen And University of Texas Medical Branch Receive Funding For Development Of Chikungunya Virus Vaccine 98
Nov 04, 2010: Novel Recombinant Chikungunya Virus Vaccine Shown To Be Safe And Effective In Multiple Animal Models 98
Nov 02, 2010: Inviragen Receives Two Therapeutic Discovery Project Grants For Vaccine Development 99
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 100
Disclaimer 101

List of Tables

Number of Products under Development for Chikungunya Fever, H2 2016 11
Number of Products under Development for Chikungunya Fever - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Chikungunya Fever - Pipeline by Abivax S.A., H2 2016 20
Chikungunya Fever - Pipeline by Arbovax, Inc., H2 2016 21
Chikungunya Fever - Pipeline by Arno Therapeutics, Inc., H2 2016 22
Chikungunya Fever - Pipeline by Bharat Biotech International Limited, H2 2016 23
Chikungunya Fever - Pipeline by Ennaid Therapeutics, LLC, H2 2016 24
Chikungunya Fever - Pipeline by Etubics Corporation, H2 2016 25
Chikungunya Fever - Pipeline by Hawaii Biotech, Inc., H2 2016 26
Chikungunya Fever - Pipeline by HSRx Group, H2 2016 27
Chikungunya Fever - Pipeline by Indian Immunologicals Limited, H2 2016 28
Chikungunya Fever - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 29
Chikungunya Fever - Pipeline by Integral Molecular, Inc., H2 2016 30
Chikungunya Fever - Pipeline by Integrated BioTherapeutics, Inc., H2 2016 31
Chikungunya Fever - Pipeline by Merck & Co., Inc., H2 2016 32
Chikungunya Fever - Pipeline by Nanotherapeutics, Inc., H2 2016 33
Chikungunya Fever - Pipeline by Profectus BioSciences, Inc., H2 2016 34
Chikungunya Fever - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 35
Chikungunya Fever - Pipeline by Themis Bioscience GmbH, H2 2016 36
Chikungunya Fever - Pipeline by Valneva SE, H2 2016 37
Chikungunya Fever - Pipeline by Vaxart, Inc., H2 2016 38
Assessment by Monotherapy Products, H2 2016 39
Number of Products by Stage and Target, H2 2016 41
Number of Products by Stage and Mechanism of Action, H2 2016 43
Number of Products by Stage and Route of Administration, H2 2016 45
Number of Products by Stage and Molecule Type, H2 2016 47
Chikungunya Fever - Dormant Projects, H2 2016 89